Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: A systematic review

Journal of Clinical Psychiatry

Volumn 67, Issue 12, 2006, Pages 1836-1855

  Ruhé, Henricus G ^a,b   Huyser, Jochanan ^a   Swinkels, Jan A ^a   Schene, Aart H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NOMIFENSINE; NORTRIPTYLINE; OXAPROTILINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DRUG HALF LIFE; DRUG RELEASE; DRUG SUBSTITUTION; HUMAN; INSOMNIA; MAJOR DEPRESSION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33845968599     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1203     Document Type: Review

References (140)

1. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996;274:740-743
2. Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders, 4: medications and other biological treatments. Can J Psychiatry 2001;46(suppl 1):38S-58S
3. Practice guideline for the treatment of patients with major depressive disorder (revision): American Psychiatric Association. Am J Psychiatry 2000;157(suppl 4):1-45
4. Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000;14:3-20
5. Mulrow CD, Williams JW Jr, Trivedi M, et al. Treatment of depression: newer pharmacotherapies. Psychopharmacol Bull 1998;34:409-795
6. Depression Guideline Panel. Depression in Primary Care, Vol 1: Detection and Diagnosis. Clinical Practice Guideline, Number 5. AHCPR Publication No. 93-0550. Rockville, Md: 1993
7. Depression Guideline Panel. Depression in Primary Care, Vol 2: Treatment of Major Depression. Clinical Practice Guideline, Number 5. AHCPR Publication No. 93-0551. Rockville, Md: 1993
8. Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998;59 (suppl 20):73-84
9. National Collaborating Centre for Mental Health. Clinical Guideline 23. Depression: Management of Depression in Primary and Secondary Care. London, England: National Institute for Clinical Excellence; 2004:1-63
10. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York, NY: Raven Press Ltd; 1995:1081-1097
11. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001;286:2947-2955
12. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003;64(suppl 1):5-12
13. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002;63:826-837
14. Lam RW, Wan DD, Cohen NL, et al. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002;63:685-693
15. Shelton RC. The use of antidepressants in novel combination therapies. J Clin Psychiatry 2003;64(suppl 2):14-18
16. Stimpson N, Agrawal N, Lewis G. Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression: systematic review. Br J Psychiatry 2002;181:284-294
17. Anderson IM. Drug treatment of depression: reflections on the evidence. Adv Psychiatr Treat 2003;9:11-20
18. Kennedy N, McDonough M. Pharmacological management of treatment-resistant depression: a clinical review. Irish J Psychol Med 2003;20:18-23
19. McIntyre RS, Muller A, Mancini DA, et al. What to do if an initial antidepressant fails? Can Fam Physician 2003;49:449-457
20. Kennedy S, McIntyre R, Fallu A, et al. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002;27:269-280
21. Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry 2001;62(suppl 6):22-29
22. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000;61(suppl 1):26-32
23. Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999;60:142-156
24. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58 (suppl 13):23-29
25. Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004;9:808-821
26. Parikh RM, Lebowitz BD. Current perspectives in the management of treatment-resistant depression. Dial Clin Neurosci 2004;6:53-60
27. Pridmore S, Turnier-Shea Y. Medication options in the treatment of treatment-resistant depression. Aust N Z J Psychiatry 2004;38:219-225
28. Mann JJ. The medical management of depression. N Engl J Med 2005;353:1819-1834
29. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001;62(suppl 18):12-17
30. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61(suppl 2):10-12
31. O'Reardon JP, Brunswick DJ, Amsterdam JD. Treatment-resistant depression in the age of serotonin: evolving strategies. Curr Opin Psychiatry 2000;13:93-98
32. Nelson JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry 1998;59(suppl 15):35-41
33. Rojo JE, Ros S, Aguera L, et al. Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl 2005;25-31, 36
34. Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999;174:297-303
35. Baker CB, Tweedie R, Duval S, et al. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 2003;17:1-9
36. Corruble E, Guelfi JD. Does increasing dose improve efficacy in patients with poor antidepressant response: a review. Acta Psychiatr Scand 2000;101:343-348
37. Ruhé HG, Huyser J, Swinkels JA, et al. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006;189:309-316
38. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999;19:427-434
39. Bauer M, Forsthoff A, Baethge C, et al. Lithium augmentation therapy in refractory depression: update 2002. Eur Arch Psychiatry Clin Neurosci 2003;253:132-139
40. Byrne S, Rothschild AJ. Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatr Serv 1997;48:835-837
41. Mischoulon D, Nierenberg AA, Kizilbash L, et al. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000;45:476-481
42. Shergill SS, Katona CL. Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists. J Affect Disord 1997;43:19-25
43. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000;61:403-408
44. Bero L, Rennie D. The Cochrane Collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA 1995;274:1935-1938
45. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-142
46. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005;22:68-76
47. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242
48. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-1172
49. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006;163:1531-1541
50. Munoz SR, Bangdiwala SI. Interpretation of kappa and B statistics measures of agreement. J Appl Stat 1997;24:105-111
51. Richtlijnontwikkeling binnen het Kwaliteitsinstituut voor de Gezondheidszorg CBO. Handleiding voor werkgroepleden. Kwaliteitsinstituut voor de Gezondheidszorg CBO. 2000. Utrecht. Kwaliteitsinstituut voor de Gezondheidszorg CBO
52. SIGN 50: A Guideline Developers' Handbook. 50. Edinburgh, Scotland: Scottish Intercollegiate Guideline Network; 2001
53. Sackett DL, Straus SE, Richardson WS, et al. Evidence-Based Medicine: How to Practice and Teach EBM. Second Edition. Edinburgh, Scotland: Churchill Livingstone; 2000
54. Moncrieff J, Churchill R, Drummond DC, et al. Development of a quality assessment instrument for trials of treatments for depression and neurosis. Int J Methods Psychiatr Res 2001;10:126-133
55. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic, comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001;62:135-142
56. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord 1998;48:47-56
57. Emrich HM, Berger M, Riemann D, et al. Serotonin reuptake inhibition vs norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry 1987;20:60-63
58. Weintraub D. Nortriptyline in geriatric depression resistant to serotonin reuptake inhibitors: case series. J Geriatr Psychiatry Neurol 2001;14:28-32
59. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-1470
60. Sajatovic M, DiGiovanni S, Fuller M, et al. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity. Clin Ther 1999;21:733-740
61. Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Ciin Psychiatry 2004;65:337-340
62. Birkenhager TK, van den Broek WW, Mulder PG, et al. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry 2004;65:1505-1510
63. Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
64. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
65. Thase ME, Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry 2001;62:683-687
66. Zarate CA, Kando JC, Tohen M, et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57:67-71
67. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995;56:30-34
68. Thase ME, Ferguson JM, Lydiard RB, et al. Citalopram treatment of paroxetine-intolerant depressed patients. Depress Anxiety 2002;16:128-133
69. Calabrese JR, Londborg PD, Shelton MD, et al. Citalopram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry 2003;64:562-567
70. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999;175:12-16
71. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001;103:66-72
72. Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry 2003;64:35-39
73. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression, I: non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988;78:668-675
74. Peselow ED, Filippi AM, Goodnick P, et al. The short- and long-term efficacy of paroxetine HCL: B: data from a double-blind crossover study and from a year-long term trial vs imipramine and placebo. Psychopharmacol Bull 1989;25:272-276
75. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002;59:233-239
76. Thase ME, Keller MB, Gelenberg AJ, et al. Double-blind crossover antidepressant study: sertraline versus imipramine [abstract]. Psychopharmacol Bull 1995;31:535
77. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001;62:413-420
78. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther 2002;24:1194-1200
79. Mischoulon D, Opitz G, Kelly K, et al. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRi with those on no recent antidepressant treatment. Depress Anxiety 2004;19:43-50
80. Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000;20:483-487
81. de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999;19:401-406
82. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423
83. Poirier MF. The concept of resistant depression and therapeutic strategies, particularly with venlafaxine. Encephale 1999;25:55-57
84. Reynaert-Dupuis C, Zdanowicz N, Leyman S, et al. Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment. Prim Care Psychiatry 2002;8:63-68
85. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1129-1134
86. Wan DD, Kundhur D, Solomons K, et al. Mirtazapine for treatment-resistant depression: a preliminary report. J Psychiatry Neurosci 2003;28:55-59
87. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 2001;50:792-801
88. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry 2003;15:17-22
89. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-465
90. Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 2003;23:365-369
91. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression, II: MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomitensine. Acta Psychiatr Scand 1988;78:676-683
92. Nolen WA, van de Putte JJ, Dijken WA, et al. L-5HTP in depression resistant to re-uptake inhibitors: an open comparative study with tranylcypromine. Br J Psychiatry 1985;147:16-22
93. Kreider MS, Bushnell WD, Oakes R, et al. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. J Clin Psychiatry 1995;56:142-145
94. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87
95. Judge R, Parry MG, Quail D, et al. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002;17:217-225
96. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75:139-153
97. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005;58:364-373
98. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137-151
99. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7:11-17
100. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001;57:161-178
101. Bruijn JA, Moleman P, Mulder PG, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed inpatients. Psychopharmacology (Berl) 1996;127:231-237
102. van den Broek WW, Birkenhager TK, Mulder PG, et al. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology (Berl) 2004;175:481-486
103. Howland RH, Thase ME. Switching strategies for the treatment of unipolar major depression. In: Rush AJ, ed. Mood Disorders: Systematic Medication Management, vol. 25. Basel, Switzerland: Karger; 1997: 56-65
104. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression: implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry 1986;43:1155-1161
105. Reimherr FW, Wood DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20:70-72
106. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:243-261
107. Beasley CM Jr, Sayler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990;20:193-200
108. Delgado PL, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55-60
109. White K, Wykoff W, Tynes LL, et al. Fluvoxamine in the treatment of tricyclic-resistant depression. Psychiatr J Univ Ott 1990;15:156-158
110. Gagiano CA, Mueller PG, Fourie J, et al. The therapeutic efficacy of paroxetine: (a) An open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients. Acta Neurol Scand 1989;80:130-131
111. Ghaziuddin N, Naylor MW, King CA. Fluoxetine in tricyclic refractory depression in adolescents. Depression 1995;2:287-291
112. Ferguson J, Cunningham L, Merideth C, et al. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry 1994;6:153-160
113. Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry 1983;44:148-152
114. Cole JO, Schatzberg AF, Sniffin C, et al. Trazodone in treatment-resistant depression: an open study. J Clin Psychopharmacol 1981;1(suppl 6):S49-S54
115. Schmauss M, Laakmann G, Dieterle D. Nomifensine: a double-blind comparison of intravenous versus oral administration in therapy-resistant depressed patients. Pharmacopsychiatry 1985;18:88-90
116. Nolen WA, Haffmans PM, Bouvy PF, et al. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189-197
117. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987;23:169-172
118. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118-123
119. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
120. Leonard BE. Neuropharmacology of antidepressants that modify central noradrenergic and serotonergic function: a short review. Hum Psychopharmacol 1999;14:75-81
121. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry 2004;65(suppl 17):5-10
122. Stahl SM. Symptoms and circuits, part 1: major depressive disorder. J Clin Psychiatry 2003;64:1282-1283
123. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry 2002;17(suppl 3):294-299
124. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004;65(suppl 4):5-10
125. Burke WJ. Selective versus multi-transmitter antidepressants: are two mechanisms better than one? J Clin Psychiatry 2004;65(suppl 4):37-45
126. Fava M, Kendler KS. Major depressive disorder. Neuron 2000;28:335-341
127. Delgado PL. How antidepressants help depression: mechanisms of action and clinical response. J Clin Psychiatry 2004;65(suppl 4):25-30
128. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
129. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
130. Mueller TI, Leon AC. Recovery, chronicity, and levels of psychopathology in major depression. Psychiatr Clin North Am 1996;19:85-102
131. Lenox-Smith AJ, Schaeffer P, Reynolds A, et al. A double blind trial of venlafaxine XR versus citalopram in patients with severe depression [abstract]. J Psychopharmacol 2001;15(suppl 3):A11
132. Thase ME, Kremer C, Rodrigues HE, et al. Mirtazapine versus sertraline after SSRI non-response [abstract]. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10-14, 2000; San Juan, Puerto Rico
133. Thase ME, Kremer C, Rodrigues H. Mirtazapine versus sertraline after SSRI nonresponse [abstract]. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
134. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-680
135. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 16):5-9
136. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003;23:92-95
137. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-61
138. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
139. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health;1976:218-222
140. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583